# Sinovac Biotech, Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Sinovac Biotech, Ltd). ## Overview Sinovac Biotech Ltd. is a biopharmaceutical company focused on researching, manufacturing, and commercializing vaccines and related biological products for human infectious diseases. Its portfolio includes established vaccines and product candidates spanning influenza, hepatitis, varicella, polio, rabies, tetanus, pneumococcal disease, and newer vaccine platforms. ## Products & services • Inactivated and live attenuated vaccines • Influenza vaccines including Panflu® and Panflu.1® • COVID-19 vaccine CoronaVac® • Hepatitis A vaccine Healive® • Sabin-strain inactivated polio vaccine (sIPV) • Pipeline vaccines: combination, recombinant protein, mRNA, antibodies - **Commercial vaccines** (75%) — Licensed and marketed vaccines used for prevention of infectious diseases. - **Pandemic and outbreak vaccines** (10%) — Vaccines developed for major public health emergencies and outbreak response. - **Prequalified global vaccines** (10%) — WHO-prequalified products suited for international procurement and public programs. - **R&D pipeline** (5%) — Combination vaccines, recombinant protein vaccines, mRNA and antibody candidates. - Inactivated and live attenuated vaccines - Influenza vaccines including Panflu® and Panflu.1® - COVID-19 vaccine CoronaVac® - Hepatitis A vaccine Healive® - Sabin-strain inactivated polio vaccine (sIPV) - Pipeline vaccines: combination, recombinant protein, mRNA, antibodies ## Customers SINOVAC sells primarily to public health systems, vaccination programs, and healthcare distributors that procure vaccines for population immunization. It also serves international agencies and local partners that need WHO-prequalified or locally adapted vaccine supply. - **Public health authorities** (primary) — Buy vaccines for national immunization programs and outbreak response. - **International procurement organizations** (primary) — Source WHO-prequalified vaccines for global health and aid programs. - **Local commercial partners** (secondary) — Distribute and register vaccines in specific countries or regions. - **Healthcare providers** (secondary) — Use selected vaccines in clinics and hospitals for patient immunization. - **Research and development partners** (emerging) — Collaborate on clinical development, technology transfer, and localized production. - National and regional public health authorities - Government vaccination programs and immunization tenders - International organizations and procurement bodies - Healthcare distributors and local market partners - Hospitals and clinics using selected vaccine products ## Geography SINOVAC is headquartered in China and operates as a global vaccine business with sales, R&D, and manufacturing tied to the Chinese market and overseas partnerships. Its products are designed for both domestic disease-prevention needs and international supply, including vaccines with WHO prequalification for broader global access. - Headquartered in China with global biopharmaceutical operations - China remains the core market for development, production, and commercialization - International partnerships support broader distribution and technology transfer - WHO-prequalified products support access in global procurement channels - Localized production initiatives help expand regional supply ## Strategy SINOVAC’s strategy centers on expanding its vaccine portfolio, progressing late-stage clinical programs, and adding newer technology platforms such as mRNA and antibody-based products. It also seeks to widen its global footprint through research partnerships, local manufacturing, and market access arrangements that support vaccine supply in multiple regions. - **Advance vaccine pipeline** (medium-term) — New products are needed to replenish the portfolio and extend growth beyond existing franchises. - **Expand global access** (medium-term) — Broader geographic reach reduces reliance on any single market and improves commercial optionality. - **Build next-generation platforms** (long-term) — New platforms can improve future competitiveness and support responses to emerging infectious diseases. - Advance combination and next-generation vaccine pipelines - Expand into mRNA and antibody-based platforms - Use WHO prequalification to support international access - Strengthen research and local production partnerships - Broaden market presence through technology cooperation ## Risks SINOVAC faces clinical, regulatory, and commercialization risk because vaccine candidates must progress through lengthy trials and market authorization processes before generating revenue. It is also exposed to demand concentration in public-sector procurement, competition from other vaccine developers, and execution risks tied to manufacturing quality, technology transfer, and global distribution. - **Clinical development failure** [high] — Vaccine candidates must complete trials and meet efficacy and safety standards before approval. - **Regulatory approval delays** [high] — Vaccines require country-by-country registration and authorization, which can slow commercialization. - **Customer concentration in public procurement** [medium] — A large share of vaccine demand is driven by governments and agencies that buy in batches and through tenders. - **Manufacturing and quality control** [high] — Biologics require stringent production consistency, cold-chain handling, and regulatory compliance. - **Competitive and technological change** [medium] — New vaccine platforms and competitors can shift demand toward newer products or lower-cost alternatives. - Clinical trials may fail or require longer development timelines - Regulatory approvals can delay launches in key markets - Public-sector demand can be uneven and tender-driven - Manufacturing quality and scale-up are critical for vaccine supply - Competition from global vaccine producers can pressure market access ## Accounting Key accounting issues include revenue recognition for vaccine sales and the timing of demand tied to procurement cycles, which can create volatility across reporting periods. Investors should also monitor impairment testing for intangible assets and goodwill, valuation of investments and wealth management products, and provisions tied to credit losses or employee incentive plans. - **Revenue timing for vaccine deliveries** — Quarterly comparability and revenue volatility - **Goodwill and intangible impairment** — Operating income and asset base - **Fair value of investments** — Other income and cash flow - **Provisioning and credit losses** — Net income and balance-sheet allowances - **Employee incentive accruals** — Operating expense and operating cash flow - Vaccine revenue may be uneven due to tender timing and delivery schedules - Inventory and production planning can affect cost of sales and working capital - Impairment testing matters for intangible assets and goodwill - Fair value changes in investments can affect other income - Employee incentive and bonus accruals can move operating cash flow --- *Last updated: 2026-09-28T12:13:56.172954+00:00*